Century Therapeutics, Inc. (IPSC) is a Biotechnology company in the Healthcare sector, currently trading at $2.37. It has a SharesGrow Score of 59/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Analyst consensus target is IPSC = $3 (+26.6% upside).
Valuation: IPSC trades at a trailing Price-to-Earnings (P/E) of -20.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.71.
Financials: revenue is $109M, +564.9%/yr average growth. Net income is $10M (loss), growing at +31.8%/yr. Net profit margin is -8.8% (negative). Gross margin is 88% (+181.7 pp trend).
Balance sheet: total debt is $44M against $159M equity (Debt-to-Equity (D/E) ratio 0.27, conservative). Current ratio is 5.97 (strong liquidity). Debt-to-assets is 19.5%. Total assets: $224M.
Analyst outlook: 7 / 9 analysts rate IPSC as buy (78%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 63/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 58/100 (Partial), Future 79/100 (Pass), Income 10/100 (Fail).
